What is Acorda Therapeutics Operating Cash Flow per Share?
Acorda Therapeutics's operating cash flow per share for the
three
months ended in Dec. 2023 was $-2.43.
Acorda Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.38.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 57.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Acorda Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
ACORQ'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -12 Med: 36.7 Max: 79.4
Current: 57.9
During the past 13 years, Acorda Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 79.40% per year. The lowest was -12.00% per year. And the median was 36.70% per year.
ACORQ's 3-Year OCF Growth Rate is ranked better than 91.33% of 807
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs ACORQ: 57.90
Acorda Therapeutics Operating Cash Flow per Share Historical Data
The historical data trend for Acorda Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Acorda Therapeutics Operating Cash Flow per Share Chart
Competitive Comparison of Acorda Therapeutics's Operating Cash Flow per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's Price-to-Operating-Cash-Flow falls into.
Acorda Therapeutics Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Acorda Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your 